Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy. Issue 8 (2nd August 2020)
- Record Type:
- Journal Article
- Title:
- Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy. Issue 8 (2nd August 2020)
- Main Title:
- Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy
- Authors:
- Manceau, Cécile
Mourey, Loic
Pouessel, Damien
Ploussard, Guillaume - Abstract:
- ABSTRACT: Introduction: Metastatic prostate cancer is a life-threatening disease and an important public health concern with prevalence rates varying drastically between high- and low-income countries. Androgen-deprivation therapy alone has been the first-line treatment option for decades, temporarily controlling disease until invariable tumor regression. At the castration-resistant stage, metastatic disease becomes lethal. In recent years several new treatments, including second-generation hormone therapies, have proven to be life-prolonging in metastatic castration-resistant prostate cancer, and at an earlier hormone-sensitive stage. Abiraterone acetate in combination with prednisone was the first approved hormone therapy demonstrating survival benefit, and represents, to date, an alternative, or a second-line treatment after taxane-based chemotherapy, in addition to androgen-deprivation therapy, in hormone sensitive, and metastatic castration-resistant prostate cancer. Area covered: We performed a literature review of papers from 2012 to 2020 using PubMed, Web of Science, and Embase searching for the safety and efficacy of abiraterone acetate in prostate cancer management. Search results were limited to phase III–IV trials and post hoc analysis of Phase III trials evaluated Abiraterone acetate in the English language. Expert opinion: This literature review confirms the role of abiraterone acetate in the therapeutic landscape with well-proven safety and efficacy,ABSTRACT: Introduction: Metastatic prostate cancer is a life-threatening disease and an important public health concern with prevalence rates varying drastically between high- and low-income countries. Androgen-deprivation therapy alone has been the first-line treatment option for decades, temporarily controlling disease until invariable tumor regression. At the castration-resistant stage, metastatic disease becomes lethal. In recent years several new treatments, including second-generation hormone therapies, have proven to be life-prolonging in metastatic castration-resistant prostate cancer, and at an earlier hormone-sensitive stage. Abiraterone acetate in combination with prednisone was the first approved hormone therapy demonstrating survival benefit, and represents, to date, an alternative, or a second-line treatment after taxane-based chemotherapy, in addition to androgen-deprivation therapy, in hormone sensitive, and metastatic castration-resistant prostate cancer. Area covered: We performed a literature review of papers from 2012 to 2020 using PubMed, Web of Science, and Embase searching for the safety and efficacy of abiraterone acetate in prostate cancer management. Search results were limited to phase III–IV trials and post hoc analysis of Phase III trials evaluated Abiraterone acetate in the English language. Expert opinion: This literature review confirms the role of abiraterone acetate in the therapeutic landscape with well-proven safety and efficacy, demonstrated in trials and post-approval studies. … (more)
- Is Part Of:
- Expert review of anticancer therapy. Volume 20:Issue 8(2020)
- Journal:
- Expert review of anticancer therapy
- Issue:
- Volume 20:Issue 8(2020)
- Issue Display:
- Volume 20, Issue 8 (2020)
- Year:
- 2020
- Volume:
- 20
- Issue:
- 8
- Issue Sort Value:
- 2020-0020-0008-0000
- Page Start:
- 629
- Page End:
- 638
- Publication Date:
- 2020-08-02
- Subjects:
- Abiraterone acetate -- second-generation androgen receptor inhibitor -- metastatic resistant-castration prostate cancer -- metastatic castration-sensitive prostate cancer -- prostate cancer
Cancer -- Treatment -- Periodicals
616.99406 - Journal URLs:
- http://informahealthcare.com ↗
http://www.future-drugs.com/loi/era ↗ - DOI:
- 10.1080/14737140.2020.1785289 ↗
- Languages:
- English
- ISSNs:
- 1473-7140
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3842.002982
British Library DSC - BLDSS-3PM
British Library HMNTS - Digital store
British Library HMNTS - ELD Digital store - Ingest File:
- 22663.xml